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Abstract
We analysed whole genome sequences of 560 breast cancers to advance understanding of the 
driver mutations conferring clonal advantage and the mutational processes generating somatic 
mutations. 93 protein-coding cancer genes carried likely driver mutations. Some non-coding 
regions exhibited high mutation frequencies but most have distinctive structural features probably 
causing elevated mutation rates and do not harbour driver mutations. Mutational signature analysis 
was extended to genome rearrangements and revealed 12 base substitution and six rearrangement 
signatures. Three rearrangement signatures, characterised by tandem duplications or deletions, 
appear associated with defective homologous recombination based DNA repair: one with deficient 
BRCA1 function; another with deficient BRCA1 or BRCA2 function; the cause of the third is 
unknown. This analysis of all classes of somatic mutation across exons, introns and intergenic 
regions highlights the repertoire of cancer genes and mutational processes operative, and 
progresses towards a comprehensive account of the somatic genetic basis of breast cancer.
Introduction
The mutational theory of cancer proposes that changes in DNA sequence, termed “driver” 
mutations, confer proliferative advantage upon a cell, leading to outgrowth of a neoplastic 
clone1. Some driver mutations are inherited in the germline, but most arise in somatic cells 
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during the lifetime of the cancer patient, together with many “passenger” mutations not 
implicated in cancer development1. Multiple mutational processes, including endogenous 
and exogenous mutagen exposures, aberrant DNA editing, replication errors and defective 
DNA maintenance, are responsible for generating these mutations1–3.
Over the past five decades, several waves of technology have advanced the characterisation 
of mutations in cancer genomes. Karyotype analysis revealed rearranged chromosomes and 
copy number alterations. Subsequently, loss of heterozygosity analysis, hybridisation of 
cancer-derived DNA to microarrays and other approaches provided higher resolution 
insights into copy number changes4–8. Recently, DNA sequencing has enabled systematic 
characterisation of the full repertoire of mutation types including base substitutions, small 
insertions/deletions, rearrangements and copy number changes9–13, yielding substantial 
insights into the mutated cancer genes and mutational processes operative in human cancer.
As for many cancer classes, most currently available breast cancer genome sequences target 
protein-coding exons8,11–15. Consequently, there has been limited consideration of 
mutations in untranslated, intronic and intergenic regions, leaving central questions 
pertaining to the molecular pathogenesis of the disease unresolved. First, the role of 
activating driver rearrangements16–18 forming chimeric (fusion) genes/proteins or 
relocating genes adjacent to new regulatory regions as observed in haematological and other 
malignancies19. Second, the role of driver substitutions and indels in non-coding regions of 
the genome20,21. Common inherited variants conferring susceptibility to human disease are 
generally in non-coding regulatory regions and the possibility that similar mechanisms 
operate somatically in cancer was highlighted by the discovery of somatic driver 
substitutions in the TERT gene promoter22,23. Third, which mutational processes generate 
the somatic mutations found in breast cancer2,24. Addressing this question has been 
constrained because exome sequences do not inform on genome rearrangements and capture 
relatively few base substitution mutations, thus limiting statistical power to extract the 
mutational signatures imprinted on the genome by these processes24,25.
Here we analyse whole genome sequences of 560 cases in order to address these and other 
questions and to pave the way to a comprehensive understanding of the origins and 
consequences of somatic mutations in breast cancer.
Results
Cancer genes and driver mutations
The whole genomes of 560 breast cancers and non-neoplastic tissue from each individual 
(556 female and four male) were sequenced (Fig.S1, Supplementary Table 1). 3,479,652 
somatic base substitutions, 371,993 small indels and 77,695 rearrangements were detected, 
with substantial variation in the number of each between individual samples (Fig.1A, 
Supplementary Table 3). Transcriptome sequence, microRNA expression, array based copy 
number and DNA methylation data were obtained from subsets of cases.
To identify new cancer genes, we combined somatic substitutions and indels in protein-
coding exons with data from other series12–15,26, constituting a total of 1,332 breast 
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cancers, and searched for mutation clustering in each gene beyond that expected by chance. 
Five cancer genes were found for which evidence was previously absent or equivocal 
(MED23, FOXP1, MLLT4, XBP1, ZFP36L1), or for which the mutations indicate the gene 
acts in breast cancer in a recessive rather than in a dominant fashion, as previously reported 
in other cancer types (Supplementary Methods section 7.4 for detailed descriptions). From 
published reports on all cancer types (http://cancer.sanger.ac.uk/census), we then compiled a 
list of 727 human cancer genes (Supplementary Table 12). Based on driver mutations found 
previously, we defined conservative rules for somatic driver base substitutions and indel 
mutations in each gene and sought mutations conforming to these rules in the 560 breast 
cancers. 916 likely driver mutations of these classes were identified (Fig.1B, Supplementary 
Table 14, Extended Data Figure 1).
To explore the role of genomic rearrangements as driver mutations16,18,19,27, we sought 
predicted in-frame fusion genes that might create activated, dominant cancer genes. 1,278 
unique and 39 infrequently recurrent in-frame gene fusions were identified (Supplementary 
Table 15). Many of the latter, however, were in regions of high rearrangement density, 
including amplicons28 and fragile sites, and their recurrence is likely attributable to 
chance27. Furthermore, transcriptome sequences from 260 cancers did not show expression 
of these fusions and generally confirmed the rarity of recurrent in-frame fusion genes. By 
contrast, recurrent rearrangements interrupting the gene footprints of CDKN2A, RB1, 
MAP3K1, PTEN, MAP2K4, ARID1B, FBXW7, MLLT4 and TP53 were found beyond the 
numbers expected from local background rearrangement rates, indicating that they 
contribute to the driver mutation burden of recessive cancer genes. Several other recurrently 
rearranged genomic regions were observed, including dominantly-acting cancer genes ETV6 
and ESR1 without consistent elevation in expression levels, L1-retrotransposition sites29 
and fragile sites. The significance of these recurrently rearranged regions remain unclear 
(Extended Data Figure 2).
Incorporation of recurrent copy number changes, including homozygous deletions and 
amplifications, generated a final tally of 1,628 likely driver mutations in 93 cancer genes 
(Fig.1B). At least one driver was identifiable in 95% of cancers. The 10 most frequently 
mutated genes were TP53, PIK3CA, MYC, CCND1, PTEN, ERBB2, chr8:ZNF703/FGFR1 
locus, GATA3, RB1 and MAP3K1 (Fig.1B, Extended Data Figure 1) and accounted for 62% 
of drivers.
Recurrent somatic mutations in non-coding genomic regions
To investigate non-coding somatic driver substitutions and indels, we searched for non-
coding genomic regions with more mutations than expected by chance (Fig.2A, 
Supplementary Table 16, Extended Data Figure 3). The promoter of PLEKHS1 (pleckstrin 
homology domain containing, family S member 1) exhibited recurrent mutations at two 
genomic positions30 (Fig.2A), the underlined bases in the sequence CAGCAAGC 
TGAACA GCTTGCTG (as previously reported30). The two mutated bases are flanked on 
either side by 9bp of palindromic sequence forming inverted repeats31. Most cancers with 
these mutations showed many base substitutions of mutational signatures 2 and 13 that have 
been attributed to activity of APOBEC DNA-editing proteins that target the TCN sequence 
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motif. One of the mutated bases is a cytosine in a TCA sequence context (shown above as 
the reverse complement, TGA) at which predominantly C>T substitutions were found. The 
other is a cytosine in ACA context which showed both C>T and C>G mutations.
The TGAACA core sequence was mutated at the same two positions at multiple locations 
elsewhere in the genome (Supplementary Table 16C) where the TGAACA core was also 
flanked by palindromes (inverted repeat), albeit of different sequences and lengths 
(Supplementary Table 16C). These mutations were also usually found in cancers with many 
signature 2 and 13 mutations (Fig.2A). TGAACA core sequences with longer flanking 
palindromes generally exhibited a higher mutation rate, and TGAACA sequences flanked by 
9bp palindromes exhibited a ~265-fold higher mutation rate than sequences without them 
(Fig.2B, Supplementary Table 16D). However, additional factors must influence the 
mutation rate because it varied markedly between TGAACA core sequences with different 
palindromes of the same length (Fig.2C). Some TGAACA-inverted repeat sites were in 
regulatory regions but others were intronic or intergenic without functional annotation 
(examples in Supplementary Table 16C) or exonic. The propensity for mutation recurrence 
at specific positions in a distinctive sequence motif in cancers with numerous mutations of 
particular signatures renders it plausible that these are hypermutable hotspots32–34, perhaps 
through formation of DNA hairpin structures35, which are single stranded at their tips 
enabling attack by APOBEC enzymes, rather than driver mutations.
Two recurrently mutated sites were also observed in the promoter of TBC1D12 (TBC1 
domain family, member 12) (q-value 4.5e-2) (Fig.2A). The mutations were characteristic of 
signatures 2 and 13 and enriched in cancers with many signature 2 and 13 mutations (Fig.
2A). The mutations were within the TBC1D12 Kozak consensus sequence 
(CCCCAGATGGTGGG)) shifting it away from the consensus36. The association with 
particular mutational signatures suggests that these may also be in a region of 
hypermutability rather than drivers.
The WDR74 (WD repeat domain 74) promoter showed base substitutions and indels (q-
value 4.6e-3) forming a cluster of overlapping mutations (Fig.2A)20. Coding sequence driver 
mutations in WDR74 have not been reported. No differences were observed in WDR74 
transcript levels between cancers with WDR74 promoter mutations compared to those 
without. Nevertheless, the pattern of this non-coding mutation cluster, with overlapping and 
different mutation types, is more compatible with the possibility of the mutations being 
drivers.
Two long non-coding RNAs, MALAT1 (q-value 8.7e-11, as previously reported12) and 
NEAT1 (q-value 2.1e-2) were enriched with mutations. Transcript levels were not 
significantly different between mutated and non-mutated samples. Whether these mutations 
are drivers, or result from local hypermutability, is unclear.
Mutational signatures
Mutational processes generating somatic mutations imprint particular patterns of mutations 
on cancer genomes, termed signatures2,24,37. Applying a mathematical approach25 to 
extract mutational signatures previously revealed five base substitution signatures in breast 
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cancer; signatures 1, 2, 3, 8 and 132,24. Using this method in the 560 cases revealed 12 
signatures, including those previously observed and a further seven, of which five have 
formerly been detected in other cancer types (signatures 5, 6, 17, 18 and 20) and two are 
new (signatures 26 and 30) (Fig.3A-B, Fig.4A, Supplementary Table 21A-C, Supplementary 
Methods 15 for further details). Two indel signatures were also found2,24.
Signatures of rearrangement mutational processes have not previously been formally 
investigated. To enable this we adopted a rearrangement classification incorporating 32 
subclasses. In many cancer genomes, large numbers of rearrangements are regionally 
clustered, for example in zones of gene amplification. Therefore, we first classified 
rearrangements into those inside and outside clusters, further subclassified them into 
deletions, inversions and tandem duplications, and then according to the size of the 
rearranged segment. The final category in both groups was interchromosomal translocations.
Application of the mathematical framework used for base substitution signatures2,24,25 
extracted six rearrangement signatures (Fig.4B, Supplementary Table 21). Unsupervised 
hierarchical clustering on the basis of the proportion of rearrangements attributed to each 
signature in each breast cancer yielded seven major subgroups exhibiting distinct 
associations with other genomic, histological or gene expression features (Fig.5, Extended 
Data Figure 4-6).
Rearrangement Signature 1 (9% of all rearrangements) and Rearrangement Signature 3 
(18% rearrangements) were characterised predominantly by tandem duplications (Fig.4B). 
Tandem duplications associated with Rearrangement Signature 1 were mostly >100kb (Fig.
4B), and those with Rearrangement Signature 3 <10kb (Fig.4B, Extended Data Figure 7). 
More than 95% of Rearrangement Signature 3 tandem duplications were concentrated in 
15% of cancers (Cluster D, Fig.5), many with several hundred rearrangements of this type. 
Almost all cancers (91%) with BRCA1 mutations or promoter hypermethylation were in this 
group, which was enriched for basal-like, triple negative cancers and copy number 
classification of a high Homologous Recombination Deficiency (HRD) index38–40. Thus, 
inactivation of BRCA1, but not BRCA2, may be responsible for the Rearrangement 
Signature 3 small tandem duplication mutator phenotype.
More than 35% of Rearrangement Signature 1 tandem duplications were found in just 8.5% 
of the breast cancers and some cases had hundreds of these (Cluster F, Fig.5). The cause of 
this large tandem duplication mutator phenotype (Fig.4B) is unknown. Cancers exhibiting it 
are frequently TP53-mutated, relatively late diagnosis, triple-negative breast cancers, 
showing enrichment for base substitution signature 3 and a high Homologous 
Recombination Deficiency (HRD) index (Fig.5) but do not have BRCA1/2 mutations or 
BRCA1 promoter hypermethylation.
Rearrangement Signature 1 and 3 tandem duplications (Extended Data Figure 7) were 
generally evenly distributed over the genome. However, there were nine locations at which 
recurrence of tandem duplications was found across the breast cancers and which often 
showed multiple, nested tandem duplications in individual cases (Extended Data Figure 8). 
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These may be mutational hotspots specific for these tandem duplication mutational 
processes although we cannot exclude the possibility that they represent driver events.
Rearrangement Signature 5 (accounting for 14% rearrangements) was characterised by 
deletions <100kb. It was strongly associated with the presence of BRCA1 mutations or 
promoter hypermethylation (Cluster D, Fig.5), BRCA2 mutations (Cluster G, Fig.5) and 
with Rearrangement Signature 1 large tandem duplications (Cluster F, Fig.5).
Rearrangement Signature 2 (accounting for 22% rearrangements) was characterised by non-
clustered deletions (>100kb), inversions and interchromosomal translocations, was present 
in most cancers but was particularly enriched in ER positive cancers with quiet copy number 
profiles (Cluster E, GISTIC Cluster 3, Fig.5). Rearrangement Signature 4 (accounting for 
18% of rearrangements) was characterised by clustered interchromosomal translocations 
while Rearrangement Signature 6 (19% of rearrangements) by clustered inversions and 
deletions (Clusters A, B, C, Fig.5).
Short segments (1-5bp) of overlapping microhomology characteristic of alternative methods 
of end joining repair were found at most rearrangements2,14. Rearrangement Signatures 2, 4 
and 6 were characterised by a peak at 1bp of microhomology while Rearrangement 
Signatures 1, 3 and 5, associated with homologous recombination DNA repair deficiency, 
exhibited a peak at 2bp (Extended Data Figure 9). Thus, different end-joining mechanisms 
may operate with different rearrangement processes. A proportion of breast cancers showed 
Rearrangement Signature 5 deletions with longer (>10bp) microhomologies involving 
sequences from short-interspersed nuclear elements (SINEs), most commonly AluS (63%) 
and AluY (15%) family repeats (Extended Data Figure 9). Long segments (more than 10bp) 
of non-templated sequence were particularly enriched amongst clustered rearrangements.
Localised hypermutation: kataegis
Focal base substitution hypermutation, termed kataegis, is generally characterised by 
substitutions with characteristic features of signatures 2 and 132,24. Kataegis was observed 
in 49% breast cancers, with 4% exhibiting 10 or more foci (Supplementary Table 21C). 
Kataegis colocalises with clustered rearrangements characteristic of rearrangement 
signatures 4 and 6 (Fig.4B). Cancers with tandem duplications or deletions of rearrangement 
signatures 1, 3 and 5 did not usually demonstrate kataegis. However, there must be 
additional determinants of kataegis since only 2% of rearrangements are associated with it. 
A rare (14/1,557 foci, 0.9%), alternative form of kataegis colocalising with rearrangements 
but with a base substitution pattern characterised by T>G and T>C mutations predominantly 
at NTT and NTA sequences was also observed (Extended Data Figure 10). This pattern of 
base substitutions most closely matches Signature 9 (Extended Data Figure 10) (http://
cancer.sanger.ac.uk/cosmic/signatures), previously observed in B lymphocyte neoplasms and 
attributed to polymerase eta activity 41.
Mutational signatures exhibit distinct DNA replication strand biases
The distributions of mutations attributable to each of the 20 mutation signatures (12 base 
substitution, two indel and six rearrangement) were explored42 with respect to DNA 
replication strand. We found an asymmetric distribution of mutations between leading and 
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lagging replication strands for many, but not all signatures42 (Fig.4A). Notably, Signatures 2 
and 13, due to APOBEC deamination, showed marked lagging replication strand bias (Fig.
4A) suggesting that lagging strand replication provides single-stranded DNA for APOBEC 
deamination. Of the three signatures associated with mismatch repair deficiency (Signatures 
6, 20, 26), only Signature 26 exhibited replicative strand bias, highlighting how different 
signatures arising from defects of the same pathway can exhibit distinct relationships with 
replication.
Mutational signatures associated with BRCA1 and BRCA2 mutations
Of the 560 breast cancers, 90 had germline (60) or somatic (14) inactivating mutations in 
BRCA1 (35) or BRCA2 (39) or showed methylation of the BRCA1 promoter (16). Loss of 
the wild-type chromosome 17 or 13 was observed in 80/90 cases. The latter exhibited many 
base substitution mutations of signature 3, accompanied by deletions of >3bp with 
microhomology at rearrangement breakpoints, and signature 8 together with CC>AA double 
nucleotide substitutions. Cases in which the wild type chromosome 17 or 13 was retained 
did not show these signatures. Thus signature 3 and, to a lesser extent, signature 8 are 
associated with absence of BRCA1 and BRCA2 functions.
Cancers with inactivating BRCA1 or BRCA2 mutations usually carry many genomic 
rearrangements. Cancers with BRCA1, but not BRCA2, mutations exhibit large numbers of 
Rearrangement Signature 3 small tandem duplications. Cancers with BRCA1 or BRCA2 
mutations show substantial numbers of Rearrangement Signature 5 deletions. No other 
Rearrangement Signatures were associated with BRCA1 or BRCA2 null cases (Clusters D 
and G, Fig.5). Some breast cancers without identifiable BRCA1/2 mutations or BRCA1 
promoter methylation showed these features and segregated with BRCA1/2 null cancers in 
hierarchical clustering analysis (Fig.5). In such cases, the BRCA1/2 mutations may have 
been missed or other mutated or promoter methylated genes may be exerting similar effects 
(Please see http://cancer.sanger.ac.uk/cosmic/sample/genomes for examples of whole 
genome profiles of typical BRCA1 null (e.g. PD6413a, PD7215a) and BRCA2 null tumours 
(e.g. PD4952a, PD4955a)).
A further subset of cancers (Cluster F, Fig.5) show similarities in mutational pattern to 
BRCA1/2 null cancers, with many Rearrangement Signature 5 deletions and enrichment for 
base substitution signatures 3 and 8. However, these do not segregate together with 
BRCA1/2 null cases in hierarchical clustering analysis, have Rearrangement Signature 1 
large tandem duplications and do not show BRCA1/2 mutations. Somatic and germline 
mutations in genes associated with the DNA double-strand break repair pathway including 
ATM, ATR, PALB2, RAD51C, RAD50, TP53, CHEK2 and BRIP1, were sought in these 
cancers. We did not observe any clear-cut relationships between mutations in these genes 
and these mutational patterns.
Cancers with BRCA1/2 mutations are particularly responsive to cisplatin and PARP 
inhibitors43–45. Combinations of base substitution, indel and rearrangement mutational 
signatures may be better biomarkers of defective homologous recombination based DNA 
double strand break repair and responsiveness to these drugs46 than BRCA1/2 mutations or 
promoter methylation alone and thus may constitute the basis of future diagnostics.
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Conclusions
A comprehensive perspective on the somatic genetics of breast cancer is drawing closer 
(please see website for individual patient genome profiles: http://cancer.sanger.ac.uk/cosmic/
sample/genomes, Methods Section 10 for orientation). At least 12 base substitution 
mutational signatures and six rearrangement signatures contribute to the somatic mutations 
found. 93 mutated cancer genes (31 dominant, 60 recessive, 2 uncertain) are implicated in 
genesis of the disease. However, dominantly-acting activated fusion genes and non-coding 
driver mutations appear rare. Additional infrequently mutated cancer genes probably exist. 
However, the genes harbouring the substantial majority of driver mutations are now known.
Nevertheless, important questions remain to be addressed. Recurrent mutational events 
including whole chromosome copy number changes and unexplained regions with recurrent 
rearrangements could harbour additional cancer genes. Identifying non-coding drivers is 
challenging and requires further investigation. Although almost all breast cancers have at 
least one identifiable driver mutation, the number with only a single identified driver is 
perhaps surprising. The roles of viruses or other microbes have not been exhaustively 
examined. Thus, further exploration and analysis of whole genome sequences from breast 
cancer patients will be required to complete our understanding of the somatic mutational 
basis of the disease.
Methods
1 Sample selection
DNA was extracted from 560 breast cancers and normal tissue (peripheral blood 
lymphocytes, adjacent normal breast tissue or skin) and total RNA extracted from 268 of the 
same individuals. Samples were subjected to pathology review and only samples assessed as 
being composed of > 70% tumor cells, were accepted for inclusion in the study 
(Supplementary Table 1).
2 Massively-parallel sequencing and alignment
Short insert 500bp genomic libraries and 350bp poly-A selected transcriptomic libraries 
were constructed, flowcells prepared and sequencing clusters generated according to 
Illumina library protocols47. 108 base/100 base (genomic), or 75 base (transcriptomic) 
paired-end sequencing were performed on Illumina GAIIx, Hiseq 2000 or Hiseq 2500 
genome analyzers in accordance with the Illumina Genome Analyzer operating manual. The 
average sequence coverage was 40.4 fold for tumour samples and 30.2 fold for normal 
samples (Supplementary Table 2).
Short insert paired-end reads were aligned to the reference human genome (GRCh37) using 
Burrows-Wheeler Aligner, BWA (v0.5.9)48. RNA-seq data was aligned to the human 
reference genome (GRCh37) using TopHat (v1.3.3) (http://ccb.jhu.edu/software/tophat/
index.shtml).
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3 Processing of genomic data
CaVEMan (Cancer Variants Through Expectation Maximization: http://cancerit.github.io/
CaVEMan/) was used for calling somatic substitutions.
Indels in the tumor and normal genomes were called using a modified Pindel version 2.0. 
(http://cancerit.github.io/cgpPindel/) on the NCBI37 genome build 49.
Structural variants were discovered using a bespoke algorithm, BRASS (BReakpoint 
AnalySiS) (https://github.com/cancerit/BRASS) through discordantly mapping paired-end 
reads. Next, discordantly mapping read pairs that were likely to span breakpoints, as well as 
a selection of nearby properly-paired reads, were grouped for each region of interest. Using 
the Velvet de novo assembler50, reads were locally assembled within each of these regions 
to produce a contiguous consensus sequence of each region. Rearrangements, represented by 
reads from the rearranged derivative as well as the corresponding non-rearranged allele were 
instantly recognisable from a particular pattern of five vertices in the de Bruijn graph (a 
mathematical method used in de novo assembly of (short) read sequences) of component of 
Velvet. Exact coordinates and features of junction sequence (e.g. microhomology or non-
templated sequence) were derived from this, following aligning to the reference genome, as 
though they were split reads.
Supplementary Table 3 for summary of somatic variants. Annotation was according to 
ENSEMBL version 58.
Single nucleotide polymorphism (SNP) array hybridization using the Affymetrix SNP6.0 
platform was performed according to Affymetrix protocols. Allele-specific copy number 
analysis of tumors was performed using ASCAT (v2.1.1), to generate integral allele-specific 
copy number profiles for the tumor cells51 (Supplementary Table 4 and 5). ASCAT was also 
applied to NGS data directly with highly comparable results.
12.5% of the breast cancers were sampled for validation of substitutions, indels and/or 
rearrangements in order to make an assessment of the positive predictive value of mutation-
calling (Supplementary Table 6).
Further details of these processing steps as well as processing of transcriptomic and miRNA 
data (Supplementary Table 7 and 8) can be found in Supplementary Methods.
4 Identification of novel breast cancer genes
To identify recurrently mutated driver genes, a dN/dS method that considers the mutation 
spectrum, the sequence of each gene, the impact of coding substitutions (synonymous, 
missense, nonsense, splice site) and the variation of the mutation rate across genes52,53 was 
used for substitutions (Supplementary Table 9). Owing to the lack of a neutral reference for 
the indel rate in coding sequences, a different approach was required (Supplementary Table 
10, Supplementary Methods for details). To detect genes under significant selective pressure 
by either point mutations or indels, for each gene the P-values from the dN/dS analysis of 
substitutions and from the recurrence analysis of indels were combined using Fisher’s 
method. Multiple testing correction (Benjamini-Hochberg FDR) was performed separately 
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for the 600+ putative driver genes and for all other genes, stratifying the FDR correction to 
increase sensitivity (as described in Sun et al. 200654). To achieve a low false discovery rate 
a conservative q-value cutoff of <0.01 was used for significance (Supplementary Table 11).
This analysis was applied to the new whole genome sequences of 560 breast cancers as well 
as a further 772 breast cancers that have been sequenced previously by other institutions.
Please see Supplementary Methods for detailed explanations of these methods.
5 Recurrence in the non-coding regions
5.1 Partitioning the genome into functional regulatory elements/gene 
features—To identify non-coding regions with significant recurrence, we used a method 
similar to the one described for searching for novel indel drivers (Supplementary Methods 
for detailed description).
The genome was partitioned according to different sets of regulatory elements/gene features, 
with a separate analysis performed for each set of elements, including exons (n=20,245 
genes), core promoters (n=20,245 genes, where a core promoter is the interval [−250,+250] 
bp from any transcription start site (TSS) of a coding transcript of the gene, excluding any 
overlap with coding regions), 5’ UTR (n=9,576 genes), 3’ UTR (n=19,502 genes), intronic 
regions flanking exons (n=20,212 genes, represents any intronic sequence within 75bp from 
an exon, excluding any base overlapping with any of the above elements. This attempts to 
capture recurrence in essential splice site or proximal splicing-regulatory elements), any 
other sequence within genes (n=18,591 genes, for every protein-coding gene, this contains 
any region within the start and end of transcripts not included in any of the above 
categories), ncRNAs (n=10,684, full length lincRNAs, miRNAs or rRNAs), enhancers 
(n=194,054) 55, ultra-conserved regions (n=187,057, a collection of regions under negative 
selection based on 1,000 genomes data 20.
Every element set listed above was analysed separately to allow for different mutation rates 
across element types and to stratify the FDR correction 54. Within each set of elements, we 
used a negative binomial regression approach to learn the underlying variation of the 
mutation rate across elements. The offset reflects the expected number of mutations in each 
element assuming uniform mutation rates across them (i.e. Esubs,element = 
Σ
 j∈{1,2,…,192}Extende (t*rj*Sj), and, Eindels,element = μindel * Sindel,element ). As covariate here 
we used the local density of mutations in neighbouring non-coding regions, corrected for 
sequence composition and trinucleotide mutation rates, that is, the t parameter of the dN/dS 
equations described in section 7.1 of Supplementary Methods. Normalised local rates were 
pre-calculated for 100kb non-overlapping bins of the genome and used in all analyses. Other 
covariates (expression, replication time or HiC) were not used here as they were not found to 
substantially improve the model once the local mutation rate was used as a covariate. A 
separate regression analysis was performed for substitutions and indels, to account for the 
different level of uncertainty in the distribution of substitution and indel rates across 
elements.
modelsubs = glm.nb(formula = nsubs ~ offset(log(Esubs)) + μlocal,subs )
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modelindels = glm.nb(formula = nindels ~ offset(log(Eindels)) + μlocal,indels )
The observed counts for each element (nsubs,element and nindels,element) are compared to the 
background distributions using a negative binomial test, with the estimated overdispersion 
parameters (θsubs and θindels) estimated by the negative binomial regression, yielding P-
values for substitution and indel recurrence for each element. These P-values were combined 
using Fisher’s method and corrected for multiple testing using FDR (Supplementary Table 
16A).
5.2 Partitioning the genome into discrete bins—We performed a genome-wide 
screening of recurrence in 1kb non-overlapping bins. We employed the method described in 
earlier section, using as covariate the local mutation rate calculated from 5Mb up and 
downstream from the bin of interest and excluding any low-coverage region from the 
estimate (Supplementary Table 16B, Extended Data Figure 3A for example). Significant hits 
were subjected to manual curation to remove false positives caused by sequencing or 
mapping artefacts.
6 Mutational signatures analysis
Mutational signatures analysis was performed following a three-step process: (i) hierarchical 
de novo extraction based on somatic substitutions and their immediate sequence context, (ii) 
updating the set of consensus signatures using the mutational signatures extracted from 
breast cancer genomes, and (iii) evaluating the contributions of each of the updated 
consensus signatures in each of the breast cancer samples. These three steps are discussed in 
more details in the next sections.
6.1 Hierarchical de novo extraction of mutational signatures—The mutational 
catalogues of the 560 breast cancer whole genome sequences were analysed for mutational 
signatures using a hierarchical version of the Wellcome Trust Sanger Institute mutational 
signatures framework 25. Briefly, we converted all mutation data into a matrix, M, that is 
made up of 96 features comprising mutations counts for each mutation type (C>A, C>G, 
C>T, T>A, T>C, and T>G; all substitutions are referred to by the pyrimidine of the mutated 
Watson–Crick base pair) using each possible 5’ (C, A, G, and T) and 3’ (C, A, G, and T) 
context for all samples. After conversion, the previously developed algorithm was applied in 
a hierarchical manner to the matrix M that contains K mutation types and G samples. The 
algorithm deciphers the minimal set of mutational signatures that optimally explains the 
proportion of each mutation type and then estimates the contribution of each signature 
across the samples. More specifically, the algorithm makes use of a well-known blind source 
separation technique, termed nonnegative matrix factorization (NMF). NMF identifies the 
matrix of mutational signature, P, and the matrix of the exposures of these signatures, E, by 
minimizing a Frobenius norm while maintaining non-negativity:
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The method for deciphering mutational signatures, including evaluation with simulated data 
and list of limitations, can be found in ref 25. The framework was applied in a hierarchical 
manner to increase its ability to find mutational signatures present in few samples as well as 
mutational signatures exhibiting a low mutational burden. More specifically, after 
application to the original matrix M containing 560 samples, we evaluated the accuracy of 
explaining the mutational patterns of each of the 560 breast cancers with the extracted 
mutational signatures. All samples that were well explained by the extracted mutational 
signatures were removed and the framework was applied to the remaining sub-matrix of M. 
This procedure was repeated until the extraction process did not reveal any new mutational 
signatures. Overall, the approach extracted 12 unique mutational signatures operative across 
the 560 breast cancers (Figure 3, Supplementary Table 21).
6.2 Updating the set of consensus mutational signatures—The 12 hierarchically 
extracted breast cancer signatures were compared to the census of consensus mutational 
signatures 25. 11 of the 12 signatures closely resembled previously identified mutational 
patterns. The patterns of these 11 signatures, weighted by the numbers of mutations 
contributed by each signature in the breast cancer data, were used to update the set of 
consensus mutational signatures as previously done in ref 25. 1 of the 12 extracted 
signatures is novel and at present, unique for breast cancer. This novel signature is consensus 
signature 30 (http://cancer.sanger.ac.uk/cosmic/signatures).
6.3 Evaluating the contributions of consensus mutational signatures in 560 
breast cancers—The complete compendium of consensus mutational signatures that was 
found in breast cancer includes: signatures 1, 2, 3, 5, 6, 8, 13, 17, 18, 20, 26, and 30. We 
evaluated the presence of all these signatures in the 560 breast cancer genomes by re-
introducing them into each sample. More specifically, the updated set of consensus 
mutational signatures was used to minimize the constrained linear function for each sample:
Here,  represents a vector with 96 components (corresponding to a consensus 
mutational signature with its six somatic substitutions and their immediate sequencing 
context) and Exposurei is a nonnegative scalar reflecting the number of mutations 
contributed by this signature. N is equal to 12 and it reflects the number of all possible 
signatures that can be found in a single breast cancer sample. Mutational signatures that did 
not contribute large numbers (or proportions) of mutations or that did not significantly 
improve the correlation between the original mutational pattern of the sample and the one 
generated by the mutational signatures were excluded from the sample. This procedure 
reduced over-fitting the data and allowed only the essential mutational signatures to be 
present in each sample (Supplementary Table 21B).
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7 Kataegis
Kataegis or foci of localized hypermutation has been previously defined 25 as 6 or more 
consecutive mutations with an average intermutation distance of less than or equal to 1,000 
bp. Kataegis were sought in 560 whole-genome sequenced breast cancers from high-quality 
base substitution data using the method described previously 25. This method likely misses 
some foci of kataegis sacrificing sensitivity of detection for a higher positive predictive value 
of kataegic foci (Supplementary Table 21C).
8 Rearrangement signatures
8.1 Clustered vs non-clustered rearrangements—We sought to separate 
rearrangements that occurred as focal catastrophic events or focal driver amplicons from 
genome-wide rearrangement mutagenesis using a piecewise constant fitting (PCF) method. 
For each sample, both breakpoints of each rearrangement were considered individually and 
all breakpoints were ordered by chromosomal position. The inter-rearrangement distance, 
defined as the number of base pairs from one rearrangement breakpoint to the one 
immediately preceding it in the reference genome, was calculated. Putative regions of 
clustered rearrangements were identified as having an average inter-rearrangement distance 
that was at least 10 times greater than the whole genome average for the individual sample. 
PCF parameters used were γ = 25 and kmin = 10. The respective partner breakpoint of all 
breakpoints involved in a clustered region are likely to have arisen at the same mechanistic 
instant and so were considered as being involved in the cluster even if located at a distant 
chromosomal site. Extended Data Table 4A summarises the rearrangements within clusters 
(“clustered”) and not within clusters (“non-clustered”).
8.2 Classification – types and size—In both classes of rearrangements, clustered and 
non-clustered, rearrangements were subclassified into deletions, inversions and tandem 
duplications, and then further subclassified according to size of the rearranged segment 
(1-10kb, 10kb-100kb, 100kb-1Mb, 1Mb-10Mb, more than 10Mb). The final category in both 
groups was interchromosomal translocations.
8.3 Rearrangement signatures by NNMF—The classification produces a matrix of 
32 distinct categories of structural variants across 544 breast cancer genomes. This matrix 
was decomposed using the previously developed approach for deciphering mutational 
signatures by searching for the optimal number of mutational signatures that best explains 
the data without over-fitting the data 25 (Supplementary Table 21D-E).
8.4 Consensus clustering of rearrangement signatures—To identify subgroups 
of samples sharing similar combinations of six identified rearrangement signatures derived 
from whole genome sequencing analysis we performed consensus clustering using the 
ConsensusClusterPlus R package 56. Input data for each sample (n=544, a subset of the full 
sample cohort) was the proportion of rearrangements assigned to each of the six signatures. 
Thus, each sample has 6 data values, with a total sum of 1. Proportions for each signature 
were mean-centred across samples prior to clustering. The following settings were used in 
the consensus clustering:
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- Number of repetitions: 1000
- pItem = 0.9 (resampling frequency samples)
- pFeature = 0.9 (resampling frequency)
- Pearson distance metric
- Ward linkage method
9 Distribution of mutational signatures relative to genomic architecture
Following extraction of mutational signatures and quantification of the exposures (or 
contributions) of each signature to each sample, a probability for each mutation belonging to 
each mutation signature (for a given class of mutation e.g. substitutions) was assigned42.
The distribution of mutations as signatures were assessed across multiple genomic features 
including replication time, strands, transcriptional strands and nucleosome occupancy. 
Please see Morganella et al for technical details, per signature results.
10 Individual patient whole genome profiles
Breast cancer whole genome profiles were adapted from the R Circos package57. Features 
depicted in circos plots from outermost rings heading inwards: Karyotypic ideogram 
outermost. Base substitutions next, plotted as rainfall plots (log10 intermutation distance on 
radial axis, dot colours: blue=C>A, black=C>G, red=C>T, grey=T>A, green=T>C, 
pink=T>G). Ring with short green lines = insertions, ring with short red lines = deletions. 
Major copy number allele (green = gain) ring, minor copy number allele ring (pink=loss), 
Central lines represent rearrangements (green= tandem duplications, pink=deletions, 
blue=inversions and gray=interchromosomal events. Top right hand panel displays the 
number of mutations contributing to each mutation signature extracted using NNMF in 
individual cancers. Middle right hand panel represents indels. Bottom right corner shows 
histogram of rearrangements present in this cancer. Bottom left corner shows all curated 
driver mutations, top and middle left panels show clinical and pathology data respectively.
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Extended Data
Extended Data Figure 1. Landscape of driver mutations
(A) Summary of subtypes of cohort of 560 breast cancers
(B) Driver mutations by mutation type
(C) Distribution of rearrangements throughout the genome. Black line represents 
background rearrangement density (calculation based on rearrangement breakpoints in 
intergenic regions only). Red lines represent frequency of rearrangement within breast 
cancer genes.
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Extended Data Figure 2. Rearrangements in oncogenes
(A) Variation in rearrangement and copy number events affecting ESR1. Clear amplification 
in topmost panel, transection of ESR1 in middle panel and focused tandem duplication 
events in lower panel.
(B) Predicted outcomes of some rearrangements affecting ETV6. Red crosses indicate exons 
deleted as a result of rearrangements within the ETV6 genes, black dotted lines indicate 
rearrangement break points resulting in fusions between ETV6 and ERC, WNK1, ATP2B1 
or LRP6
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Extended Data Figure 3. Recurrent non-coding events in breast cancers
(A) Manhattan plot demonstrating sites with most significant p-values as identified by 
binning analysis. Purple highlighted sites were also detected by the method seeking 
recurrence when partitioned by genomic features.
(B) Locus at chr11:65Mb which was identified by independent analyses as being more 
mutated than expected by chance. In the lowermost panel, a rearrangement hotspot analysis 
identified this region as a tandem duplication hotspot, with nested tandem duplications noted 
at this site. Partitioning the genome into different regulatory elements, an analysis of 
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substitutions and indels identified lncRNAs MALAT1 and NEAT1 (topmost panels) with 
significant p-values.
Extended Data Figure 4. Copy number analyses
(A) Frequency of copy number aberrations across the cohort. Chromosome position along x-
axis, frequency of copy number gains (red) and losses (green) y-axis.
(B) Identification of focal recurrent copy number gains by the GISTIC method 
(Supplementary Methods)
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(C) Identification of focal recurrent copy number losses by the GISTIC method
(D) Heatmap of GISTIC regions following unsupervised hierarchical clustering. 5 cluster 
groups are noted and relationships with expression subtype (basal=red, luminal B=light blue, 
luminal A=dark blue), immunohistopathology status (ER, PR, HER2 status – 
black=positive), abrogation of BRCA1 (red) and BRCA2 (blue) (whether germline, somatic 
or through promoter hypermethylation), driver mutations (black=positive), HRD index (top 
25% or lowest 25% - black=positive).
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Extended Data Figure 5. miRNA analyses
Hierarchical clustering of the most variant miRNAs using complete linkage and Euclidean 
distance. miRNA clusters were assigned using the Partitioning Algorithm using Recursive 
Thresholding (PART) method. Five main patient clusters were revealed. The horizontal 
annotation bars show (from top to bottom): PART cluster group, PAM50 mRNA expression 
subtype, GISTIC cluster, rearrangement cluster, lymphocyte infiltration score and 
histological grade. The heatmap shows clustered and centered miRNA expression data (log2 
transformed). Details on colour coding of the annotation bars are presented below the 
heatmap.
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Extended Data Figure 6. Rearrangement cluster groups and associated features
(A) Overall survival by rearrangement cluster group
(B) Age of diagnosis
(C) Tumor grade
(D) Menopausal status
(E) ER status
(F) Immune response metagene panel
(G) Lymphocytic infiltration score
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Extended Data Figure 7. Contrasting tandem duplication phenotypes
Contrasting tandem duplication phenotypes of two breast cancers using chromosome X. 
Copy number (y-axis) depicted as black dots. Lines represent rearrangements breakpoints 
(green=tandem duplications, pink=deletions, blue=inversions, black=translocations with 
partner breakpoint provided). Top panel, PD4841a, is overwhelmed by large tandem 
duplications (>100kb, RS1) while PD4833a has many short tandem duplications (< 10kb, 
RS3) appearing as “single” lines in its plot.
Nik-Zainal et al. Page 22
Nature. Author manuscript; available in PMC 2016 November 02.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Extended Data Figure 8. Hotspots of tandem duplications
A tandem duplication hotspot occurring in 6 different patients
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Extended Data Figure 9. Rearrangement breakpoint junctions
(A) Breakpoint features of rearrangements in 560 breast cancers by Rearrangement 
Signature.
(B) Breakpoint features in BRCA and non-BRCA cancers
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Extended Data Figure 10. Signatures of focal hypermutation
(A) Kataegis and alternative kataegis occurring at the same locus (ERBB2 amplicon in 
PD13164a). Copy number (y-axis) depicted as black dots. Lines represent rearrangements 
breakpoints (green=tandem duplications, pink=deletions, blue=inversions). Topmost panel 
showing a ~10Mb region including the ERBB2 locus. Second panel from top zooms in 10-
fold to a ~1Mb window highlighting co-occurrence of rearrangement breakpoints, with copy 
number changes and three different kataegis loci. Third panel from top demonstrates 
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kataegis loci in more detail. Log10 intermutation distance on y axis. Black arrow 
highlighting kataegis. Blue arrows highlighting alternative kataegis.
(B) Sequence context of kataegis and alternative kataegis identified in this dataset.
Supplementary Material
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Figure 1. Cohort and catalogue of somatic mutations in 560 breast cancers.
(A) Catalogue of base substitutions, insertions/deletions, rearrangements and driver 
mutations in 560 breast cancers (sorted by total substitution burden). Indel axis limited to 
5,000(*).
(B) Complete list of curated driver genes sorted by frequency (descending). Fraction of ER 
positive (left, total 366) and ER negative (right, total 194) samples carrying a mutation in the 
relevant driver gene presented in grey. Log10 p-value of enrichment of each driver gene 
towards the ER positive or ER negative cohort is provided in black. Highlighted in green are 
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genes for which there is new or further evidence supporting these as novel breast cancer 
genes.
Nik-Zainal et al. Page 33
Nature. Author manuscript; available in PMC 2016 November 02.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 2. Non-coding analyses of breast cancer genomes
(A) Distributions of substitution (purple dots) and indel (blue dots) mutations within the 
footprint of five regulatory regions identified as being more significantly mutated than 
expected is provided on the left. The proportion of base substitution mutation signatures 
associated with corresponding samples carrying mutations in each of these non-coding 
regions, is displayed on the right.
(B) Mutability of TGAACA/TGTTCA motifs within inverted repeats of varying flanking 
palindromic sequence length compared to motifs not within an inverted repeat.
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(C) Variation in mutability between loci of TGAACA/TGTTCA inverted repeats with 9bp 
palindromes.
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Figure 3. Extraction and contributions of base substitution signatures in 560 breast cancers
(A) Twelve mutation signatures extracted using Non-Negative Matrix Factorization. Each 
signature is ordered by mutation class (C>A/G>T, C>G/G>C, C>T/G>A, T>A/A>T, T>C/
A>G, T>G/A>C), taking immediate flanking sequence into account. For each class, 
mutations are ordered by 5’ base (A,C,G,T) first before 3’ base (A,C,G,T).
(B) The spectrum of base substitution signatures within 560 breast cancers. Mutation 
signatures are ordered (and coloured) according to broad biological groups: Signatures 1 and 
5 are correlated with age of diagnosis, Signatures 2 and 13 are putatively APOBEC-related, 
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Signatures 6, 20 and 26 are associated with MMR deficiency, Signatures 3 and 8 are 
associated with HR deficiency, Signatures 18, 17 and 30 have unknown etiology. For ease of 
reading, this arrangement is adopted for the rest of the manuscript. Samples are ordered 
according to hierarchical clustering performed on mutation signatures. Top panel shows 
absolute numbers of mutations of each signature in each sample. Lower panel shows 
proportion of each signature in each sample.
(C) Distribution of mutation counts for each signature in relevant breast cancer samples. 
Percentage of samples carrying each signature provided above each signature.
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Figure 4. Additional characteristics of base substitution signatures and novel rearrangement 
signatures in 560 breast cancers
(A) Contrasting transcriptional strand asymmetry and replication strand asymmetry between 
twelve base substitution signatures.
(B) Six rearrangement signatures extracted using Non-Negative Matrix Factorization. 
Probability of rearrangement element on y-axis. Rearrangement size on x-axis. Del= 
deletion, tds = tandem duplication, inv = inversion, trans = translocation.
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Figure 5. Integrative analysis of rearrangement signatures
Heatmap of rearrangement signatures (RS) following unsupervised hierarchical clustering 
based on proportions of RS in each cancer. 7 cluster groups (A-G) noted and relationships 
with expression (AIMS) subtype (basal=red, luminal B=light blue, luminal A=dark blue), 
immunohistopathology status (ER, PR, HER2 status – black=positive), abrogation of 
BRCA1 (purple) and BRCA2 (orange) (whether germline, somatic or through promoter 
hypermethylation), presence of 3 or more foci of kataegis (black=positive), HRD index (top 
25% or lowest 25% - black=positive), GISTIC cluster group (black=positive) and driver 
Nik-Zainal et al. Page 39
Nature. Author manuscript; available in PMC 2016 November 02.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
mutations in cancer genes. miRNA cluster groups : 0=red, 1=purple, 2=blue, 3=light blue, 
4=green, 5=orange. Contribution of base substitution signatures in these 7 cluster groups is 
provided in the lowermost panel.
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